Pharma major Dr Reddy's Laboratories Ltd has entered into an agreement with the US-based Oceana Therapeutics to sell and distribute its drug Deflux in India. Deflux is indicated for the treatment of vesicoureteral reflux (VUR – a malformation of urinary bladder) in children. “By leveraging the therapeutic value of Deflux with the strengths of Dr Reddy's resources, we foresee a significant opportunity to serve a wider patient population in India with an important treatment for VUR,” Mr Gregory Stokes, Executive Vice-President, Business Development, Oceana, said in a release hosted on company's Web site. The global sales of Deflux in 2008 were at about $30 million, the New Jersey-based company said. When contacted, a functionary of Dr Reddy's told Business Line that though Deflux was not a big product, it would help the Hyderabad-based company increase its offerings in the segment. The financial aspects of the agreement were not disclosed.
Dr Reddy's pact with US co for Deflux
Published on
May 17, 2011 10:30
Tags